United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

21 Feb 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare... (more)


Beta: 2.59
Market Cap(Mil.): $130.07
Shares Outstanding(Mil.): 20.84
Dividend: --
Yield (%): --


  DRNA.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -3.20 -- --
ROI: -76.78 8.92 14.45
ROE: -169.72 10.08 15.96

Eli Lilly makes bet on gene-silencing drug firm Dicerna

Eli Lilly and Co is spending $100 million for a stake in Dicerna Pharmaceuticals Inc as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology.

29 Oct 2018

Eli Lilly makes bet on gene-silencing drug firm Dicerna

* Lilly to pay Dicerna $100 mln upfront plus $100 mln for stake

29 Oct 2018

Earnings vs. Estimates